PMID- 35568817
OWN - NLM
STAT- MEDLINE
DCOM- 20220518
LR  - 20220716
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 22
IP  - 1
DP  - 2022 May 14
TI  - Novel biomarkers of inflammation in heart failure with preserved ejection 
      fraction: analysis from a large prospective cohort study.
PG  - 221
LID - 10.1186/s12872-022-02656-z [doi]
LID - 221
AB  - BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a syndrome 
      with a heterogeneous cluster of causes, including non-resolving inflammation, 
      endothelial dysfunction, and multi-organ defects. The present study's objective 
      was to identify novel predictors of HFpEF. METHODS: The study analyzed the 
      Multi-Ethnic Study of Atherosclerosis (MESA) to assess the association of 
      specific markers of inflammation with new onset of HFpEF (interleukin-2 [IL-2], 
      matrix metalloproteinase 3 [MMP3], large low-density lipoprotein cholesterol 
      [LDL-C], and medium high-density lipoprotein cholesterol [HDL-C]). The study 
      included men and women 45 to 84 years of age without cardiovascular disease at 
      baseline. The primary outcome was the multivariate association of the 
      hypothesized markers of inflammation with new-onset of HFpEF versus participants 
      without new-onset heart failure. Participants with missing data were excluded. 
      RESULTS: The present analysis included 6814 participants, 53% female, with a mean 
      age of 62 years. Among the entire cohort, HFpEF was diagnosed in 151 (2.2%) 
      participants and heart failure with reduced ejection fraction (HFrEF) was 
      diagnosed in 146 (2.1%) participants. Participants were followed for the outcome 
      of heart failure for a median 13.9 years. Baseline IL-2 was available for 2861 
      participants. The multivariate analysis included 2792 participants. Of these, 
      2668 did not develop heart failure, 62 developed HFpEF, 47 developed HFrEF, and 
      15 developed unclassified heart failure. In the multivariate regression model, 
      IL-2 was associated with new-onset HFpEF (OR, 1.00058; 95% confidence interval, 
      1.00014 to 1.00102, p = 0.009) but not new-onset HFrEF. In multivariate analysis, 
      MMP3, large LDL-C, and medium HDL-C were not associated with HFpEF or HFrEF. 
      CONCLUSION: These findings portend IL-2 as an important component of suboptimal 
      inflammation in the pathogenesis of HFpEF.
CI  - (c) 2022. The Author(s).
FAU - Carris, Nicholas W
AU  - Carris NW
AUID- ORCID: 0000-0001-8904-5034
AD  - Taneja College of Pharmacy, University of South Florida, 12901 Bruce B. Downs 
      Blvd MDC 30, Tampa, FL, 33612, USA. carris@usf.edu.
FAU - Mhaskar, Rahul
AU  - Mhaskar R
AD  - Morsani College of Medicine, University of South Florida, 560 Channelside Drive, 
      Tampa, FL, 33602, USA.
FAU - Coughlin, Emily
AU  - Coughlin E
AD  - Morsani College of Medicine, University of South Florida, 560 Channelside Drive, 
      Tampa, FL, 33602, USA.
FAU - Bracey, Easton
AU  - Bracey E
AD  - Taneja College of Pharmacy, University of South Florida, 12901 Bruce B. Downs 
      Blvd MDC 30, Tampa, FL, 33612, USA.
FAU - Tipparaju, Srinivas M
AU  - Tipparaju SM
AD  - Taneja College of Pharmacy, University of South Florida, 12901 Bruce B. Downs 
      Blvd MDC 30, Tampa, FL, 33612, USA.
FAU - Halade, Ganesh V
AU  - Halade GV
AUID- ORCID: 0000-0002-5351-9354
AD  - Morsani College of Medicine, University of South Florida, 560 Channelside Drive, 
      Tampa, FL, 33602, USA. ghalade@usf.edu.
LA  - eng
GR  - R01 DK119066/DK/NIDDK NIH HHS/United States
GR  - R01 HL144788/HL/NHLBI NIH HHS/United States
GR  - R01 HL132989/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220514
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
RN  - 0 (Biomarkers)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Interleukin-2)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Biomarkers
MH  - Cholesterol, LDL
MH  - Cohort Studies
MH  - Female
MH  - *Heart Failure
MH  - Humans
MH  - Inflammation/diagnosis
MH  - Interleukin-2
MH  - Male
MH  - Matrix Metalloproteinase 3
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Stroke Volume
PMC - PMC9107006
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Heart failure
OT  - Inflammation
OT  - Interleukin-2
COIS- No, I declare that the authors have no competing interests as defined by BMC, or 
      other interests that might be perceived to influence the results and/or 
      discussion reported in this paper.
EDAT- 2022/05/16 06:00
MHDA- 2022/05/18 06:00
PMCR- 2022/05/14
CRDT- 2022/05/15 00:24
PHST- 2022/03/07 00:00 [received]
PHST- 2022/04/27 00:00 [accepted]
PHST- 2022/05/15 00:24 [entrez]
PHST- 2022/05/16 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/05/14 00:00 [pmc-release]
AID - 10.1186/s12872-022-02656-z [pii]
AID - 2656 [pii]
AID - 10.1186/s12872-022-02656-z [doi]
PST - epublish
SO  - BMC Cardiovasc Disord. 2022 May 14;22(1):221. doi: 10.1186/s12872-022-02656-z.